

ASX RELEASE

10 December 2021

Entitlement Offer Completed

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to announce it has had good support from existing shareholders of the Company for its fully underwritten, non-renounceable entitlement offer which was announced on 8 November 2021 (**Entitlement Offer**).

Eligible Shareholders were entitled to apply for up to 1 fully paid ordinary share (**New Shares**) for every 4 shares they held on Thursday 16 November 2021 (**Record Date**) and were also able to subscribe for New Shares over and above their Entitlement (capped at a maximum representing up to 100% of their Entitlement) under a Shortfall Facility.

In addition to the New Shares, participants in the Entitlement Offer will receive free attaching options on the basis of 1 option for every 3 New Shares issued (**Options**). A total of 12.9 million Options are expected to be issued in connection with the Entitlement Offer. The Options will have an exercise price of \$0.28 and expire on 31 December 2023. The Company will apply to the ASX to have these Options listed.

A total of 38,727,835 New Shares will be issued under the Entitlement Offer at an issue price of \$0.18 raising a total of \$6.97 million. The Entitlement Offer was well supported by the Company’s largest shareholders with Platinum Investment Management Ltd, Blueflag Holdings Pty Ltd and Acorn Capital Limited all committing to take up their full entitlements amounting to \$2.2 million in a “firm in relief” arrangement with the Underwriter, Taylor Collison.

In addition to the subscriptions noted above Amplia received additional valid applications from eligible shareholders for 6.4 million New Shares (\$1.15 million). The resultant shortfall of 19.9 million New Shares will be placed by the Underwriter.

Amplia’s CEO and Managing Director Dr John Lambert commented that “Amplia’s Board and Management are very grateful for the ongoing support of our shareholders and advisors. This Entitlement Offer, together with the Placement we completed in November, puts our Company in a strong position to reach several value inflexions over the next 12-18 months. Our team is now focussed on delivery of these milestones.”

The proceeds from the Entitlement Offer will be used to fund the first stage of a Phase 2 clinical trial for AMP945, manufacturing and further pre-clinical studies as well as providing the Company with additional working capital.

The Company advises that settlement of the Entitlement Offer will occur on Tuesday, 14 December 2021 (rather than Monday, 13 December 2021).

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

For Further Information

Dr. John Lambert

Chief Executive Officer

john@ampliatx.com

www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and fibrosis and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. In addition, the company is pursuing the potential of its FAK inhibitors in pulmonary fibrosis.